Physician profile
Julia Padgett
NPI 1588373187
$1,918.84
in general payments reported to CMS, 2019-2025
14 companies · $976 in 2025
The $976 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $818 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $573.84 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $320.83 | 2025 | Freestyle Libre 3, Cardiomems |
| Abbvie INC. | $301.84 | 2023-2025 | |
| Pfizer INC. | $190.68 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $141.93 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.12 | 2024-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $70.04 | 2024-2025 | Wegovy |
| Amgen INC. | $58.45 | 2024-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $54.93 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $46.58 | 2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $31.09 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $16.78 | 2025 | Contrave |
| Corcept Therapeutics | $16.20 | 2025 | Korlym |
| Exact Sciences Corporation | $13.53 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.